A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. - Wikidata - awgldk - TriplyDB

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.

http://www.wikidata.org/entity/Q34582560

about

Atypical teratoid/rhabdoid tumors: challenges and search for solutions Pediatric high-grade glioma: biologically and clinically in need of new thinking Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells features Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Molecular biology of pediatric brain tumors and impact on novel therapies.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.Advances in Management of Pediatric Ependymomas.Investigational new drugs for brain cancer.Inhibition of epidermal growth factor signaling by the cardiac glycoside ouabain in medulloblastoma.Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT.Proteomic analysis of Medulloblastoma reveals functional biology with translational potential.

P2860

Q28066905-76CEEBCC-0847-4986-BB26-C678E8605C35 Q33777868-CD62C6A8-F509-43C0-BA16-528CEEAE303A Q35150189-20E8C000-A3F7-4533-B96C-72482ED1C4FB Q35818728-BFC265C2-436A-49A2-88DE-D42A0EC490FF Q36600202-A0ABD60E-96E1-47BF-9510-4F806D8E96D5 Q37193464-9C0CDCBF-8778-4BBA-B6EC-EB3BAC3A8F43 Q38359284-EE65CE00-7D29-494F-BA94-750F501948DF Q38583655-A10CD3E1-805F-4479-A19D-0BECA8D6B09A Q38586580-81B86A90-F3CC-4E21-9B58-2ECB37026457 Q38832510-84B238F8-F6BB-4353-BC76-4B9AEFD68FEB Q38972699-8717B483-108B-4A83-89B2-4AF2E01ABDD2 Q42212236-BBD2011B-FEA9-4AD1-8B26-173F7C4835FA Q47133403-ED155328-A231-4C59-AA2D-E95933DE4571 Q48212195-EFA04280-DF50-4D3D-83E3-AB38B1529C41 Q50528739-F189D897-A430-4AAA-B7A6-9EC413FC6B5E Q52638234-6729BE42-330D-4B64-B2EC-DD9E224E310D Q52682258-6441206D-DAE5-4BE0-8DC4-50447FFB3C0A Q52715479-CC97AF4D-39D4-4C03-AAFE-FFB654C646FB Q54374687-EAA0C982-F589-409C-B4C5-DB4C06E9B34D Q55479624-A54B121B-57EA-401D-9FE2-92694959EDBE

P2860

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.

http://www.wikidata.org/entity/Q34582560

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A molecular biology and phase ...... brain tumor consortium study.

@ast

A molecular biology and phase ...... brain tumor consortium study.

@en

A molecular biology and phase ...... brain tumor consortium study.

@nl

type

label

A molecular biology and phase ...... brain tumor consortium study.

@ast

A molecular biology and phase ...... brain tumor consortium study.

@en

A molecular biology and phase ...... brain tumor consortium study.

@nl

prefLabel

A molecular biology and phase ...... brain tumor consortium study.

@ast

A molecular biology and phase ...... brain tumor consortium study.

@en

A molecular biology and phase ...... brain tumor consortium study.

@nl

P1433

Q34582560-430B895F-5CC3-4DC6-A880-1E929077011D

P1476

Q34582560-DB58D046-E1CA-41BC-BBE4-10215E15C9AC

P2093

Q34582560-00E6E4D5-0048-4CF9-A383-D9EA86F3B26C

Q34582560-0712DB25-99D0-48BA-B7E1-A0DEE158459A

Q34582560-4863DFDB-F695-4237-904D-D21EE5DA8572

Q34582560-539FDA1B-8A61-48E5-94A0-0A5C85920FB8

Q34582560-7E12D1EB-E3AD-415D-B00B-E2E96CF6E846

Q34582560-88334AC5-26CA-47D2-A716-7900CC6604FB

Q34582560-89A044B1-0EC1-401A-93F8-851CBCB03D48

Q34582560-9020FD41-F961-47AC-BB04-7A1A6D15BF04

Q34582560-C14A7DA7-25C3-4D12-814B-2F2A16EC9D6A

Q34582560-CF6871F5-A2AD-4215-BE86-0921BB602FF0

P2860

Q34582560-01627A8C-D705-4CD7-899A-5C81AFC3BA90

Q34582560-01C0E53E-77E7-4D58-B5E8-BE3B92D32A41

Q34582560-0338BD2F-EC81-444C-AF0E-FB76C0E06084

Q34582560-0CD73F1D-C3E8-4D09-997A-58CB5B3BB9C5

Q34582560-0F937F03-5D7B-4B6E-A6B7-7402E5D8D434

Q34582560-1AD90960-59AD-4A3A-ABEF-EC3FF983AE0F

Q34582560-1E29606F-F875-4D03-B194-D05A5C980C34

Q34582560-32F2A386-D8AB-43F5-9E82-C4D334579F14

Q34582560-3E46AD4A-5929-4F12-B17F-C722BE6620CB

Q34582560-4D4719CA-161F-49DA-AB71-910CC355A260

P2888

Q34582560-4855EAE4-C37A-4E5F-89E8-ABDB5F6250A1

P304

Q34582560-DE07914D-B756-4790-90B6-AD5788370F38

P31

Q34582560-794BFAC2-B44A-4DF3-85A4-238AC102E7E0

P356

Q34582560-1A70D048-BD56-47A7-81D6-50FE298062CA

P433

Q34582560-7A83009B-C102-430F-B994-B97A4DFB3C60

P478

Q34582560-4840ADCC-5F3B-43BD-8747-D56145CD8CCD

P50

Q34582560-13B720FF-AF91-4ECA-ACA3-8AA313CF3D5B

Q34582560-3F990160-7457-4E96-BB09-5A4A52EBD0EA

P577

Q34582560-C6EAD2B5-112B-4ACE-BF0F-04C3DFE44D68

P6179

Q34582560-889ADCEB-9B1A-40AB-9356-6D04E2447180

P698

Q34582560-DDCA8C3F-D3AC-43CF-A78D-5BE2B19F61BB

P921

Q34582560-04CC3C32-706E-4572-908D-77E4A1EB894D

P932

Q34582560-25BC1FBD-4009-4461-AA0B-527C12463388

P356

S11060-013-1166-7

P1433

Journal of Neuro-Oncology

P1476

A molecular biology and phase ...... brain tumor consortium study.

@en

P2093

Amar Gajjar

http://www.w3.org/2001/XMLSchema#string

Arzu Onar-Thomas

http://www.w3.org/2001/XMLSchema#string

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

J Russell Geyer

http://www.w3.org/2001/XMLSchema#string

James M Boyett

http://www.w3.org/2001/XMLSchema#string

Larry E Kun

http://www.w3.org/2001/XMLSchema#string

Paula Schaiquevich

http://www.w3.org/2001/XMLSchema#string

Richard J Gilbertson

http://www.w3.org/2001/XMLSchema#string

Roger J Packer

http://www.w3.org/2001/XMLSchema#string

Stewart Goldman

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma.

P2888

s11060-013-1166-7

P304

173-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-013-1166-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1040862366

http://www.w3.org/2001/XMLSchema#string

P698

23836190

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4246636

http://www.w3.org/2001/XMLSchema#string